Since the introduction of breast implants in the 1960s, their safety has been debated extensively, even resulting in a temporary ban (1992-2006) on silicone-gel implants for cosmetic indications by the US Food and Drug Administration (FDA).
1 However, consistent associations of silicone breast implants with adverse events, such as breast cancer, autoimmune diseases, and connective tissue diseases have not been substantiated, as recently underlined by 2 meta-analyses.
2,3 The risk for anaplastic large-cell lymphoma (ALCL) in the breast in relation to breast implants was not discussed in these studies.
2,3